Company: INDP
Filing Date: 2025-03-13
Form Type: 10-K
Source: 0001493152-25-010136
Chunk: 534

Company: Indaptus Therapeutics, Inc.
Filing Date: 2025-03-13
Form: 10-K
Item: Item 2
Chunk 534
---
, and Dr. Martell. Mr. Hayes serves as the Chairperson of the committee. Our Board has affirmatively determined
that each of Mr. Hayes, Ms. Karah, and Dr. Martell is independent for purposes of serving on an audit committee under Rule 10A-3 promulgated
under the Exchange Act and the Nasdaq Rules, including those related to Audit Committee membership.

The
members of our Audit Committee meet the requirements for financial literacy under the applicable Nasdaq rules. In addition, our Board
of Directors has determined that Mr. Hayes qualifies as an “audit committee financial expert,” as such term is defined in
Item 407(d)(5) of Regulation S-K, and under the similar Nasdaq Rules requirement that the Audit Committee have a financially sophisticated
member.

78

Compensation
Committee

Our
Compensation Committee is responsible for assisting the Board in the discharge of its oversight responsibilities relating to the evaluation
of our executive officers (including the Chief Executive Officer), determining the compensation of our executive officers, and overseeing
the management of risks associated therewith. In fulfilling its purpose, our Compensation Committee has the following principal duties:

    ●
    reviewing and
    approving, or recommending for approval by the Board, our overall compensation strategy and policies, including evaluating risks
    associated with our compensation policies and practices;

    ●
    reviewing and approving,
    or recommending for approval by the Board, the compensation of our CEO and our other executive officers;

    ●
    overseeing and administering
    our cash and equity incentive plans;

    ●
    reviewing and making recommendations
    to the Board of Directors with respect to non-employee director compensation;

    ●
    reviewing and discussing
    annually with management our “Compensation Discussion and Analysis,” to the extent required; and

    ●
    preparing the annual compensation
    committee report, to the extent required by SEC rules.

The
Compensation Committee generally considers the Chief Executive Officer’s recommendations when making decisions regarding the compensation
of executive officers (other than the Chief Executive Officer). Pursuant to the Compensation Committee’s charter, which is available
on the Investors page of our website at www.indaptusrx.com, the Compensation Committee has the authority to retain or obtain the
advice of compensation consultants, legal counsel and other advisors to assist in carrying out its responsibilities. The Compensation
Committee did not engage the services of a compensation consultant in 2023.

The
Compensation